Ganley Pharmaceuticals FXR agitant ASC42 has been approved in the United States to conduct a clinical trial of NASH adaptation.

ASC42 is a new highly effective nonsteroidal nonsteroidal nifer X-subject (FXR) astigtor developed in-house by Ganley Pharmaceuticals and expected to be best in-class.
two NASH animal models, ASC42 showed significant improvements in liver fat degeneration, inflammation and fibrosis.
ASC42 is an oral tablet developed by proprietary technology and has the characteristics of stability at room temperature.
also has two clinically-staged drug candidates in its NASH pipeline, ASC40 and ASC41, respectively.
ASC40 (TVB-2640) is an oral fatty acid synthase (FASN) inhibitor, phase II clinical (FASCINATE-1) data conducted in the United States show that ASC40 (TVB-2640) significantly reduced liver fat content, in the 50 mg dose group response rate of up to 61%.
ASC41 is a pre-drug with liver targeting and its active ingredient (ASC41-A) is selective β THR-A.
ASC42 can be used alone or in union with ASC40 or ASC41.
note: There are deletions in the original text.